Kamada Pharma (KMDA) Enterprise Value to EBITDA Ratio

The share price retrospective for Kamada Ltd. (KMDA) on the GURU.Markets platform demonstrates an EV/EBITDA of 8.77. Kamada Ltd. (KMDA) operates advanced plasma fractionation facilities with continuous updates to its purification systems. Stringent FDA requirements and a robust patent portfolio protect the business from new entrants. However, the risk of synthetic analogs and competition with global industry leaders create significant challenges for growth.

Kamada Ltd - KMDA Company Value to EBITDA (period 11/23/2025 - 11/11/2026)

Comprehensive metric breakdowns and analytics for kamada.com (KMDA)

- current price and projected stock value:

Stock Price Kamada Corp|KMDA - Analyst Median Target

- market capitalization details:

Market Valuation Kamada Pharma|KMDA - Full Business Value

- business book valuation details:

Book Value per Share Kamada|KMDA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio kamada.com|KMDA - Total Business Assets

- debt burden and liquidity indicators:

- financial results and valuation multiples details:

KMDA - Final Profit|Expected Profit Kamada Ltd.|KMDA - Price to Earnings Ratio|Forward P/E Multiple Kamada Ltd.|KMDA - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kamada Pharma|KMDA - Operating profit EBITDA|Net earnings per share (EPS TTM) Kamada|KMDA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months kamada.com|KMDA - Net earnings per share growth this year|Earnings growth forecast for next year Kamada Ltd.

Fundamental valuation:Kamada Corp KMDA

The EV/EBITDA multiple determines business value by combining market capitalization and net debt relative to operating profit. This calculation allows for the neutralization of tax burdens and debt structures when comparing assets. By analyzing business valuation through EV/EBITDA trends, an investor can identify the market premium relative to the company's value. For Kamada Ltd. (KMDA), this indicator is critical as it reflects the capitalization efficiency of profits derived from the sale of Glassia protein and specialized vaccines.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Tx - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (Abeona Therapeutics)|MREO: EV/EBITDA Multiple|protalix.com (PLX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pliant Therapeutics Inc|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rein Therapeutics, Inc. (RNTX)|Enterprise Value to EBITDA Ratio gelteq.com GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PLRZ - EV/EBITDA Multiple|AEZS: EV/EBITDA Multiple|Cyclo Therapeutics, Inc (CYTH) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to EBITDA Ratio reneopharma.com (RPHM)|EV/EBITDA Multiple CSCI